New TB vaccine candidate takes on BCG in Mid-Stage trial
NCT ID NCT06997367
First seen May 03, 2026 · Last updated May 16, 2026 · Updated 3 times
Summary
This study tests a new tuberculosis vaccine called MTBVAC in 164 healthy adolescents and adults, comparing it to the standard BCG vaccine. The goal is to see if MTBVAC is safe and triggers a stronger immune response. Participants include both people never exposed to TB and those who have been exposed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUBERCULOSIS (TB) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
AIIMS-Delhi
New Delhi, 110029, India
-
Guru Teg Bahadur Hospital
Delhi, 11009, India
Conditions
Explore the condition pages connected to this study.